GlassScriptPhysician profile
Redemption G Geronimo
NPI 1497723803
$1,917.80
in general payments reported to CMS, 2019-2025
23 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $40.07 · 2021: $214 · 2022: $197 · 2023: $338 · 2024: $104 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $519.85 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $209.18 | 2023-2025 | Arexvy, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.21 | 2019-2024 | Jardiance |
| Sunovion Pharmaceuticals INC. | $124.83 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $122.94 | 2023-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $108.89 | 2022-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $96.00 | 2019-2022 | |
| Ucb, INC. | $86.18 | 2022 | |
| Sanofi Pasteur INC. | $71.63 | 2019-2025 | |
| Pfizer INC. | $70.24 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $63.40 | 2019 | |
| Abbvie INC. | $57.60 | 2021-2025 | |
| Ultragenyx Pharmaceutical INC. | $31.75 | 2021 | |
| Esperion Therapeutics, INC. | $27.34 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.15 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $23.53 | 2025 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $23.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.14 | 2021 | |
| Lilly USA, LLC | $21.38 | 2025 | Mounjaro, Zepbound |
| Cranial Technologies, INC | $19.88 | 2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $19.40 | 2023 | Entyvio |
| Merck Sharp & Dohme LLC | $16.76 | 2019 | |
| Boston Scientific Corporation | $13.52 | 2023 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Redemption Geronimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.